Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s stock price was down 12% during trading on Friday . The stock traded as low as $26.20 and last traded at $26.33. Approximately 71,365 shares traded hands during mid-day trading, an increase of 178% from the average daily volume of 25,632 shares. The stock had previously closed at $29.91.
Wall Street Analyst Weigh In
Several research analysts have commented on NBTX shares. Leerink Partners set a $14.00 price target on shares of Nanobiotix in a report on Thursday, September 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a report on Wednesday. Finally, HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a report on Friday, September 19th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Nanobiotix presently has an average rating of "Hold" and an average target price of $11.00.
Read Our Latest Stock Analysis on Nanobiotix
Nanobiotix Price Performance
The stock has a 50-day moving average of $11.75 and a two-hundred day moving average of $6.84.
Hedge Funds Weigh In On Nanobiotix
A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC bought a new position in Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is owned by hedge funds and other institutional investors.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
